Argos Therapeutics to Present Data Related to Clinical Development Program for AGS-003 During 2014 ASCO Annual Meeting

Argos Therapeutics, Inc. logo

Results from study of long-term survival in metastatic renal cell carcinoma patients treated with combination of AGS-003 plus sunitinib to be presented May 31; update on ADAPT Phase 3 trial to be presented June 2.

DURHAM, N.C., May 12, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company will present updates from two research studies involving AGS-003, the company's investigational fully personalized immunotherapy for cancer, at the American Society of Clinical Oncology (ASCO) Annual Meeting being held at the McCormick Place Exhibition Center in Chicago, Illinois May 30 – June 3, 2014.

Argos will be presenting results for the completed Phase 2 combination study and ongoing pivotal ADAPT trial involving AGS-003 plus standard targeted therapy in poster sessions during the meeting as follows:

  • "Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib", presented by Asim Amin, MD, PhD, on Friday, May 30, 2014, 1:00 PM - 4:00 PM; abstract #4524, poster board #16; also discussed from 4:30 – 5:45 PM in room s100bc.

  • "Enrollment insights in the synchronous mRCC population: An update from the ongoing ADAPT Phase 3 study experience", presented by Robert A. Figlin, MD, FACP, on Monday, June 2, 2014, 1:15 PM - 5:00 PM; abstract #TPS4599, poster board #162A.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company also plans to report data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

CONTACT: Media: Lynn Granito Berry & Company Public Relations lgranito@berrypr.com (212) 253-8881 Investors: Angeli Kolhatkar Burns McClellan akolhatkar@burnsmc.com (212) 213-0006

Source:Argos Therapeutics, Inc.